2024年EPO关于抗癌专利与创新的研究报告（103页）

Investment Rating - The report does not explicitly provide an investment rating for the industry. Core Insights - Since 2015, there has been a 70% increase in cancer-related innovations, driven by advancements in cancer treatment technologies such as immunotherapy and gene therapy, as well as diagnostic technologies like liquid biopsies [15][12][13]. - The United States is a dominant leader in cancer-related innovations, accounting for nearly 50% of international patent families (IPF) from 2002 to 2021, with significant contributions from both American and Chinese applicants in recent years [16][9]. - Germany leads in Europe for cancer-related innovations, but countries like the UK, France, Switzerland, and the Netherlands are rapidly catching up [18][19]. - Universities and public research institutions play an increasingly significant role in cancer-related innovations, contributing nearly one-third of all IPF globally [20][19]. - Despite geographical differences among leading applicants, patent activity in cancer treatment is primarily concentrated in the United States [21][20]. Summary by Sections Section 1: Introduction - The report aims to provide unique insights into the technological landscape and latest innovation trends in the cancer field, utilizing global patent data as a measure of innovation [14][28]. Section 2: Cancer Burden - In 2020, there were approximately 19.3 million new cancer cases and about 10 million cancer deaths globally, highlighting cancer as a major health threat [13][40]. - The report discusses the historical milestones in cancer research and the significant advancements in treatment and diagnosis that have occurred over the decades [39][38]. Section 3: Overview of Cancer-Related Patents - The report outlines the overall trends in patent applications related to cancer technologies, noting a significant increase in IPF from 2015 to 2021 [15][14]. - It highlights the role of leading applicants and the contributions of universities and public research organizations in the patent landscape [20][19]. Section 4: Geographical Distribution of Cancer-Related Innovations - The report details the geographical distribution of cancer-related innovations, emphasizing the leadership of the United States and the growing contributions from China and European countries [16][18]. Section 5: Development of Specific Cancer Technologies - The report discusses advancements in cancer diagnostics and treatment methods, including the rise of targeted therapies and immunotherapies, which are reshaping cancer care [52][53].